Neurocrine Biosciences, Inc. (NBIX)
Nasdaq: NBIX · Biological Products, (No Diagnostic Substances) · San Diego, CA · filing with the SEC since 1996
Grade7.4
◀ Past 8.4● Present 7.8▶ Future 5.8
Who owns Neurocrine Biosciences, Inc.
As filed with the SECHolders of 5% or more
4
Blackrock, Inc. holds 12.1% of Common Stock, as its SCHEDULE 13G/A filed Apr 28, 2025 says.
Directors and officers
21
report now, of 31 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 28, 2025 · Common Stock
Dodge & Cox
SCHEDULE 13G · filed May 14, 2025 · Common Stock
Vanguard Capital Management
SCHEDULE 13G · filed Apr 30, 2026 · Common Stock
JPMorgan Chase & Co.
SCHEDULE 13G/A · filed Oct 15, 2026 · Common Stock, $0.001 par value · 6.3% in Jul 27, 2026
State Street Corporation
SCHEDULE 13G · filed Feb 5, 2025 · COMMON STOCK · reported falling below 5%
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%, from 10.2% in Mar 6, 2025
What NBIX reports owning in othersstakes of 5% or more, and other ties
6 subsidiaries in 4 countries, from the list filed with the 10-K filed Feb 11, 2026.
Insider tradesForm 4
50sales
0purchases
50sales on a scheduled plan
14people selling
$77.4Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 5, 2025 to Nov 5, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 5, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window15 of 31 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Gorman Kevin Charles | Chief Executive Officer | 1 | $37.8M | 1 | 0 | $0 |
| Cooke Julie | Chief Human Resources Officer | 5 | $5.8M | 5 | 0 | $0 |
| Gano Kyle | Chief Executive Officer | 2 | $4.8M | 2 | 0 | $0 |
| Morrow George J | director | 13 | $4.5M | 13 | 0 | $0 |
| Lippoldt Darin | Chief Legal Officer | 5 | $4.2M | 5 | 0 | $0 |
| Sherwin Stephen A | director | 5 | $4.1M | 5 | 0 | $0 |
| Delaet Ingrid | Chief Regulatory Officer | 5 | $3.7M | 5 | 0 | $0 |
| Onyia Jude | Chief Scientific Officer | 2 | $3.5M | 2 | 0 | $0 |
| Rastetter William H | director | 1 | $2.7M | 1 | 0 | $0 |
| Pops Richard F | director | 1 | $2.4M | 1 | 0 | $0 |
| Lyons Gary A | President and CEO | 1 | $2.3M | 1 | 0 | $0 |
| Norwalk Leslie V | director | 5 | $2.0M | 5 | 0 | $0 |
| Benevich Eric | Chief Commercial Officer | 2 | $1.2M | 2 | 0 | $0 |
| Boyer David W. | Chief Corp. Affairs Officer | 2 | $700,000 | 2 | 0 | $0 |
| Abernethy Matt | Chief Financial Officer | 1 | $400,000 | 1 | 0 | $0 |